Other, less specific, AXL-targeting drugs including the multi-kinase inhibitors cabozantinib (VEGFR2, MET and AXL), crizotinib (MET, ALK and AXL), amuvatinib (PDGFR, c-KIT and AXL) and bosutinib (Src, ABL and AXL) have already been tested in cancer patients with promising results and manageable and short-lasting side-effects [39–42]. This evidence concerns the gene MET and cancer.